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Recent advances in our understanding of the molecular biology of lymphatic endothelial cells have revealed that these vessels, besides their
known function in tissue homeostasis and immunity, constitute conduits for the tumor cells to metastasize. One of the factors that contribute to
tumor spread is the acquisition of an angiogenic phenotype as a response to the onset of tumor hypoxia. To our knowledge, little is known about
the effects of low oxygen levels on the lymphatic vasculature. Therefore, we used cDNA microarrays to study the transcriptional changes
occurring in hypoxia exposed lymphatic endothelial cells. Our analysis was then complemented by functional assays showing that these cells
responded with increased attachment to the extracellular matrix, delayed proliferation and production of reactive oxygen species. Differential
expression of genes involved in these processes such as NADPH oxidase 4, the tissue inhibitor of metalloproteinase 3, and TGFβ induced protein
I, was found. Hypoxia was also found to increase mRNA levels of the cytokine CXCL-12 and its receptor CXCR4. Moreover, adhesion
experiments revealed that hypoxia increased the binding of non-small cell lung carcinoma cells to this endothelium in a CXCR4 dependent way.
We thus illustrate the response of lymphatic endothelial cells to hypoxia and suggest targets to study tumor metastasis through these vessels.
© 2007 Elsevier B.V. All rights reserved.Keywords: Lymphatic; Hypoxia; Adhesion; Endothelium; Gene Expression1. Introduction
Lymphatic vessels are important for physiology as they
collect interstitial tissue fluid, assist in the absorption of dietary
fat, and sustain immune function by guiding antigen presenting
cells towards the lymph nodes [1]. Small lymphatic vessels have
specific structural characteristics that facilitate the trafficking of
cells; they are devoid of basal membrane and pericytes and have
no smooth muscle cells covering them. Additionally, the
lymphatic endothelial cells (LEC) are attached to the extra-
cellular matrix by elastic fibers in such a way that the vessel
diameter is regulated by the changes occurring in the interstitial
pressure [2].⁎ Corresponding author. Oncology. Centre for Applied Medical Research,
Avenida Pío XII, 55, 31008 Pamplona, Spain. Tel.: +34 948 19 47 00x1006; fax:
+34 948 19 47 19.
E-mail address: arouzaut@unav.es (A. Rouzaut).
0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.03.001Physiological lymphangiogenesis has been observed in three
settings: embryonic development, wound healing and tissue
regeneration. In all of these cases, the oxygen supply through the
blood vessels is challenged as a consequence of a deficient
vasculature. The lymphatic vessels are also involved in maladies
such as lymphedema and cancer. In fact, the presence of tumor
cells in the lymph node is a key prognostic indicator for most
human solid cancers [3]. Debate still rages in the scientific arena
regarding the presence and functionality of lymphatic vascu-
lature inside the tumor. Even though increases in lymphatic
vascularization in the peritumoral areas of solid carcinomas have
been proven, evidence as to the presence of intra-tumor lympha-
tics is less conclusive [4].
Most solid cancers evolve towards a state in which their
growth surpasses that of the adjacent blood vessels setting off
a gradient of oxygen levels inside the tumor and fostering an
angiogenic response [5]. Therefore, fast growing tumor
endothelial cells frequently constitute a defective, leaky
vasculature that compromises their oxygen supply, causing
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hypoxia from the endothelium itself [6]. These responses are
mainly regulated at the genome level by a family of basic-
helix–loop–helix proteins called hypoxia-inducible transcrip-
tion factors (HIFs) [7] which regulate the transcription of
angiogenic factors, vasoactive substances, and inflammatory
mediators involved in cell survival, vessel permeability, and
the formation of new vessels [8]. The production of new
vasculature will eventually facilitate the metastatic spread of
cancer cells [9].
Interestingly, Manalo et al. [10] have recently published on
the changes induced in gene expression in endothelial cells
engineered to overexpress HIF-1 alpha. Furthermore, two
parallel studies published in 2004 by Schereurer [11] and
Ning [12] focused on the overall transcriptomic response of
human umbilical vein and arterial endothelial cells to hypoxia.
In spite of the presence of overlapping gene expression, a
significant degree of specific response exists depending on the
endothelial cell lineage, a view which is consistent with recent
publications concerning endothelial cell diversity [13].
Despite the previously mentioned information on blood
endothelial cells' response to hypoxia, it is not known how
lymphatic endothelial cells behave in a low oxygen environ-
ment. In the present study we therefore aim to present a
genome-wide analysis of hypoxia-dependent regulation of gene
expression in lymphatic endothelial cells. To obtain a more
complete picture of this phenomenon, we accompany the
transcriptome analysis with some functional assays that allow
us to conclude that hypoxia alters the adhesive properties of
human LEC to the extracellular matrix. We also determine that
increased lung carcinoma cell adhesion to LEC under hypoxia
occurs through a CXCR4 dependent pathway. Greater knowl-
edge of the mechanisms involved in the response of the
lymphatic endothelium to hypoxia will help to further develop
molecular strategies devoted to modulate cancer spread through
these vessels.
2. Materials and methods
2.1. Cell culture
Cryopreserved primary human lymphatic endothelial cells (LEC) were
obtained from Clonetics (HMVEC pooled human microvascular endothelial
cells, Walkersville, USA). These cells were described as being 99% LEC [14]
and contained endothelial cells derived from three different individuals. They
were cultured on collagenized 10 cm2 dishes in endothelial complete medium
EGM (Clonetics), which consists of EBM2 supplemented with EGM-2 MV
SingleQuots (Clonetics) containing FBS, hydrocortisone, EGF, VEGF, FGFb,
insulin-like growth factor 1, ascorbic acid and gentamicin/amphotericin. The
NSCLC (adenocarcinoma A549 and NCI-H1299, squamous cell carcinoma,
NCI-H157) were purchased from, Promochem SL, Barcelona, Spain and were
grown in RPMI 1640 medium (GIBCO) supplemented with 10% FBS and
Penicillin-streptomycin at 100 U/ml. All cell cultures were maintained at 37 °C
in a humidified 5% CO2 incubator.
2.2. Cell exposure to hypoxia
5×105 LEC cells were cultured on collagenized 10 cm2 dishes in EGM
medium until they reached 70% confluence. 24 h before hypoxia exposure the
cell culture media was replaced with media depleted of FGF and VEGF for 12–14 h. After that time, LEC were incubated under hypoxia (1% O2) in a multi-gas
incubator MCO-18 M from Sanyo (Leicestershire, UK) for the time periods
indicated for each experimental condition. All the experiments were performed
with primary LEC at passage 5. H1299 NSCLC cells were exposed to hypoxia in
0.1% FBS RPMI medium.
2.3. Immunocytochemistry
Lymphatic endothelial cells were grown in 4-well chamber slides (5×104
cells/well) in EGM. For immunohistochemical analyses, LEC were fixed in 20 g
polyethylene glycol/L ethanol 50% for 24 h at 4 °C and post-fixed for 5 min in
acetone/methanol (1:1 v/v). Samples were then blocked with 10% goat serum
(Dako, Glostrups, Denmark) for 30 min at room temperature. Afterwards,
primary antibodies were added overnight at 4 °C as follows: anti-human
podoplanin 1:50 (Abcam, Cambridge, UK), anti-human PAL-E 1:50 (Abcam),
and anti-human CD31 1:100 (Sigma, Steinheim, Germany). Samples were
washed and incubated with mouse or rabbit Envision polymer (Dako) for 30 min
and were visualized after treatment with diaminobenzidine (DABplus, Dako).
All the preparations were counterstained with hematoxylin and mounted in DPX
mountant medium (BDH Chemicals, Poole, UK).
2.4. RNA Isolation and microarray hybridization
Total RNAwas extracted with Trizol (Gibco, Carlsbad, USA) following the
manufacturer's instructions and further purified by use of the RNeasy total RNA
isolation kit (Qiagen, Maryland, USA). For transcriptome analysis, Human
Genome U133 Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA) were
employed. This array contained 56,400 probes derived from 22,000 human
genes (http://affymetrix.com/products/arrays/index.affx). RNA samples from
three independent experiments were pooled, and RNA processing, labeling and
hybridization was performed at the core facility of Progenika S.A (Derio, Spain).
Briefly, 5 μg of total RNAwas reverse transcribed using the One-Cycle cDNA
synthesis kit from Affymetrix. cRNA was biotin labeled according to IVT
Labeling kit from the same manufacturer. The labeled cRNAwas hybridized and
the GeneChip® arrays were scanned using the Affymetrix Scanner 3000.
Measurements of the absolute mRNA expression levels were performed
by use of the Microarray Suite 5.0 software (Affymetrix) and expression
values were calculated using the Gene Chip Operating Software (GCOS 1.1,
Affymetrix). In order to minimize the variations derived from the
hybridization conditions, all probe sets were scaled to a target intensity
value of 75 to allow inter-array comparisons. The one-sided Wilcoxon Signed
Rank Test was the statistical method employed to generate the detection P-
value. To give an estimate of the magnitude and direction of changes in gene
expression, Tukey's Biweight method was used to generate a mean of the log
ratios of probe pair intensities across the two arrays. All the genes were
subjected to a filter of a 1.5 fold change in gene expression, and a detection
value of P<0.005 was deemed to be significant. The primary data discussed
in this publication have been deposited in NCBIs Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO
Series accession number GSE5579.
In order to further minimize the presence of false positives, we only
considered that a gene was overexpressed when a probe was detected as
“present” in LEC exposed to hypoxia, had an “increase” call, and showed a
signal log ratio above 1.0. Likewise, we considered that a gene was
downregulated when the corresponding probe was detected as “present” in the
control sample, showed a “decreased” call and had a signal log ratio below −1.0.
A complete list of the selected differential expressed genes is available as
Supplementary Table 2.
We followed our analysis by using a bioinformatics approach designed to
classify the differentially expressed genes according to ontology groups using
the Unigene database and Onto-Express (http://vortex.cs.wayne.edu).
2.5. cDNA synthesis and semiquantitative PCR
One microgram from each RNA sample was reverse-transcribed into cDNA
using the Superscript II reverse transcriptase (Promega, Madison, USA) in a
final reaction volume of 20 μl.
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were conducted in a total volume of 20 μl using the PCR Master Mix from
Promega. Primers were designed using the Primer 3 software (http://frodo.wi.
mit.edu/cgi-bin/primer3) and can be found in the supplementary Table 1.
cDNA samples were denatured for 5 min at 94 °C, and amplified for 30
cycles of 94 °C for 45 s, gene specific Tm for 45 s, and 72 °C for 1 min,
followed by a 5-min cycle for final extension at 72 °C. PCR products were
resolved by electrophoresis in 2% agarose gel and visualized by ethidium
bromide staining.
2.6. Validation of gene expression by Real-Time RT-PCR
Real-time quantitative PCR was performed using the SYBR green PCR
master mix and the iCycler instrument from Applied Biosystems, (Warring-
ton, UK). Cycling conditions were: 1 cycle of 50 °C for 2 min and 95 °C for
2 min, followed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min and 1
final cycle of 95 °C for 15 s, 60 °C for 1 min and 95 °C for 15 s. All samples
were run in triplicate in a final volume of 25 μl that included 1 μl of cDNA
and 20 μM of each gene-specific primer. Fold changes in the expression of
each target mRNA relative to β-actin were calculated based on the threshold
cycle (Ct) as 2-Δ(ΔCt), where ΔCt=Ct target−Ct β-actin and Δ(ΔCt)=
ΔCt1%−ΔCt21%.
2.7. Determination of cell proliferation by the neutral red
incorporation assay
2×103 LEC cells/well were cultured for 12 h in complete EGM on 96-well
plates (TPP, St. Louis MO, USA). After that time, cells were incubated for 24,
48, 72, 96 and 120 h under hypoxia or normoxia in medium depleted from
VEGF and bFGF. Medium was removed and cells were incubated for 1 h at
37 °C with 200 μl of fresh media and 50 μl of neutral red solution at a
concentration of 1 mg/ml (Sigma). The incorporated dye was extracted by the
addition of 100 μl of NaH2PO4–ethanol 50%. Cells were washed and their
absorbance was read at 540 nm in a TECAN sunrise microtiter plate reader
(Hayward, CA, USA).
2.8. Determination of apoptosis
Cell apoptosis was determined by annexin V-PI staining (Serotec, Oxford,
UK) following the manufacturer's instructions. Cell fluorescence was measured
using a Becton Dickinson FACScan (San José, CA, USA), with an excitation
wavelength of 488 nm.
2.9. Measurement of intracellular reactive oxygen species
LEC were cultured in 96 wells as stated above and loaded for 10 min with
5 μM 5(6)-carboxy-2′,7′-dichlorofluorescein diacetate (Carboxy-DCFDA,
Fluka). Afterwards the cells were washed twice with PBS and incubated
under hypoxia (1% O2) for different time periods. Carboxy-DCFDA
fluorescence was measured at an excitation wavelength of 485 nm and emission
at 520 nm on a Polar star Galaxy, BMG fluorescent plate reader (Offenburg,
Germany).
2.10. Lymphatic endothelial cell adhesion assays
To measure LEC adhesion to several extracellular matrix components, the
cells were labeled with 10 μM calcein-AM (Fluka, Steinheim, Germany) for
20 min at 37 °C at a concentration of 1×106 cells/ml in adhesion-medium
(RPMI 0.5% BSA, 20 mM HEPES). 96-well plates (TPP) were coated with
5 μg/cm2 type I rat tail collagen (BD Bioscience, San Diego, CA USA), 5 μg/
cm2 collagen type IV, 1 μg/cm2 fibronectin, 0.1 μg/cm2 vitronectin, 1 μg/cm2
laminin, 0.1 μg/cm2 gelatin or 3% BSA (all from Sigma) for 2 h at 37 °C. Plates
were blocked for 1 h at 37 °C with 1% BSA. 1×104 LEC cells/well were seeded
on the matrix coated 96-well plate and were allowed to attach for 30 min at
37 °C. Non-adherent cells were removed after that time by gentle washing. The
quantification of adherent cells was performed on a Polar star Galaxy, BMG
plate reader (Lab Technologies, Durham, NC, USA), using an excitationwavelength of 485 nm and an emission filter of 520 nm. Six replicates were
made for each condition.
To measure NSCLC cells adhesion to the lymphatic endothelium, 3×104
calcein-labeled tumor cells were seeded on top of each LEC monolayer. The
tumor-LEC co-cultures were allowed to interact for 30 min at 37 °C. Adhered
cells were then washed and quantified as before. For blocking experiments, 5 ng/
ml of anti CXCR4 antibody (MAB172, R&D Systems, Inc., Minneapolis, MN)
or non-specific IgG (MAB004, R&D Systems) was added 30 min before the
assay.
2.11. Flow cytometric analysis of CXCR4
For the cytometric analyses, cells were resuspended in phosphate-buffered
saline buffer and incubated with anti-CXCR4 antibody (MAB172, R&D
Systems) or the appropriate isotype control (MAB004, R&D Systems) at room
temperature for 30 min. Cells were washed and incubated with fluorescein
isothiocynate conjugated anti-mouse antibodies (Molecular Probes, Invitrogen
Corp, Barcelona, Spain) at room temperature for 30 min. Samples were finally
analyzed on a FACScan flow cytometer using Cellquest software (BD
PharMingen, San Diego, CA, USA).
2.12. Migration assay of NSCLC through an endothelial lymphatic
monolayer
Cell migration was assayed using a modified Boyden chamber (BD
Biosciences) of 8-μm pore size filters. A total of 4×104 endothelial lymphatic
cells were seeded in EBM2medium on the upper chamber and allowed to adhere
overnight. 3×104 NSCLC cells previously growth in normoxia or hypoxia for
24 h, were added to the top chamber in migration medium (RPMI supplemented
with 0.5% BSA) and allow to migrate for 8 h. For blocking experiments, 5 ng/ml
of anti CXCR4 antibody (MAB172, R&D Systems) was added 30 min before
the assay. After incubation NSCLC cells were removed from the upper chamber
by swiping with cotton swabs, fixated and stained with a crystal-violet solution.
Migrated NSCLC on the lower surface of the filter were counted using an ocular
micrometer. At least four high-powered fields were counted for each sample.
3. Results and discussion
The commercially available neonatal HMVEC pooled
endothelial cells had been described as being 99% LEC [14].
We initiated our study by confirming their lineage identity by
immunohistochemical analysis of the expression of three
endothelial cell markers: Pal-E specific for blood endothelial
cells, CD31 as pan-endothelial marker and podoplanin, a
membrane protein specific to lymphatic endothelial cells. As
seen in Fig. 1A, pooled HMVEC cells were devoid of Pal-E
expression, but all of them expressed both podoplanin and
CD31, confirming their identity as LEC. It has been recently
described that blood endothelial cells respond to hypoxia by
increasing their expression of pro-angiogenic mediators such as
VEGF and bFGF and that this induction is HIF-1alpha
dependent [15,10]. The production of these molecules seems
crucial to allow cellular survival and to maintain its structure
under adverse conditions. We therefore went on, as a
preliminary step towards a full transcriptomic characterization
of LEC response to hypoxia, to ascertain if chronic short term
hypoxia could provoke changes in the mRNA expression of
various vascular endothelial growth factors along with other
well-known hypoxia regulated genes. LEC were cultured under
1% oxygen for 24 h as described in Materials and methods and
the mRNA levels of VEGF-A, -C and -D, and the hypoxia
driven genes HIF-2α, adrenomedulin, ceruloplasmin, the
Fig. 1. Changes induced by low oxygen exposure in the expression of
endothelial growth factors and hypoxia responsive genes in LEC. (A)
Characterization of LEC population by immunocytochemistry was performed
using podoplanin as a specific lymphatic endothelial cell marker, PAL-E as a
specific blood marker and the pan-endothelial marker CD31. Human Umbilical
vein endothelial cells (HUVEC) were used as negative control (B) Analysis by
semiquantitative PCR of mRNA expression levels for several growth factors and
hypoxia responsive genes in LEC cultured under normoxia (N) or hypoxia (H,
1% pO2).
Table 1
Hypoxia responsive genes upregulated in LEC grown under low oxygen
conditions
Chip ID Name Gene
symbol
Gene ID Mean Probes a
Angiogenesis
210512_s_at vascular
endothelial
growth factor
VEGF AF022375 4.01 4.00
209946_at vascular
endothelial
growth factor C
VEGFC U58111 2.83 1.00
223333_s_at angiopoietin-like 4 ANGPTL4 AF169312 7.48 2.00
210095_s_at insulin-like growth
factor binding
protein 3
IGFBP3 M31159 3.28 2.00
AMP metabolism
202588_at adenylate kinase 1 AK1 NM_000476 2.30 1.00
225342_at adenylate kinase 3 AK3 AK026966 3.49 3.00
Glucose transporters
207038_at solute carrier
family 16,
member 6
SLC16A6 NM_004694 4.14 2.00
201250_s_at solute carrier
family 2,
member 1
SLC2A1 NM_006516 8.00 1.00
222088_s_at solute carrier
family 2,
member 14
SLC2A14 AA778684 2.70 2.00
202499_s_at solute carrier
family 2,
member 3
SLC2A3 NM_006931 3.23 3.00
Iron metabolism
204846_at ceruloplasmin
(ferroxidase)
CP NM_000096 11.53 4.00
a Number of overexpressed probes.
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were measured by semiquantitative PCR. The expression of all
the mRNA products except VEGF-D increased 24 h after
exposure to hypoxia (Fig. 1B). We also measured HIF-1 alpha
expression and, as described in other endothelial cell systems, it
peaked 3 h after hypoxic exposure, reaching baseline levels 12 h
later (data not shown). From these data we assumed a
transcriptional response to hypoxia in LEC and judged it
worth studying in more depth.
To portray the changes produced in such an intricately
regulated event, we used microarray analysis to compare the
gene expression pattern between LEC exposed to acute (1% O2)
hypoxia and those grown under a normoxic atmosphere (21%
O2). Total RNA expression was analyzed using Human Genome
U-133 Plus 2.0 arrays from Affymetrix that contains 54,600
oligonucleotide probes obtained from 22,000 different genes.
As a first step in our analysis, we set up a threshold of 1.5 foldfor differentially expressed gene products, since this cutoff
contained many of the well-known hypoxia response factors
such as the proangiogenic factors VEGF-A, angiopoyetin-L4
(ANGPTL4) or the glucose transporters 1 and 3 (Table 1). This
initial analysis revealed that 1872 gene probes were regulated
by hypoxia in LEC, constituting 7.6% out of the total gene
input, with nearly the same numbers of up (879) and
downregulated (993) probes. Detailed information about the
expression intensities of each probe is provided as supplemen-
tary Table 1, available at the journal website.
In order to focus on a reduced number of genes, a more
stringent analysis was performed. This second gene selection
was based on a selection criterion of 2 fold change, a detection
P-value<0.005 and their presence in control (for repressed
genes) or in hypoxia exposed samples (for induced genes). As a
result, the number of differentially expressed genes was
narrowed to almost one third (621 gene probes). From these,
344 were upregulated and 277 showed decreased mRNA
expressions under low oxygen conditions. It is noteworthy that
40% of the downregulated gene probes belonged to transcrip-
tion factors or genes involved in chromatin remodeling,
suggesting a strong transcriptional repression by low oxygen
levels (see supplementary Table 2).
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those differentially expressed genes. Therefore a bioinformatics
approach was adopted that made use of the GO categories to
classify the selected genes according to their molecular
function. The ontologically based classification identified 378
differently expressed genes represented in 475 out of the 621
gene probes whose function had already been described, while
the 146 remaining gene probes corresponded to non-annotated
sequences. Annotated genes were grouped into the following
categories: cell division, metabolism, apoptosis, oxidative
stress, adhesion and cytoskeleton. We also categorized as
miscellaneous all of the genes that could not be clearly
classified in any of the former groups. A summarized
representation of the results obtained is represented in Fig. 2A
and is given in full detail in Supplementary Table 2.
In order to confirm the results obtained by the microarray
analysis, we selected some genes to be validated by real time
PCR on three new RNA samples (Table 3). We chose the
following for their key implication in the processes described
below: the TGF β induced protein INHBA1 was validated since
it is implicated in the inhibition of the cell cycle. We corroborate
the expression of arginase 2, SOD2 and NOX4 since they
participate in oxidative stress responses. Regarding cell
adhesion, the differential expression of PCDH10, PCDH12,
CD109 and CD34, involved in cell-cell adhesion was confirmed
while this was not the case for claudin 3 and EPSTL1 also
checked. RT-PCR analysis confirmed increased expression ofFig. 2. Overall representation of genomic and functional changes in hypoxia expo
molecular function based on gene ontology; the percentages in the figure represent t
expressed genes. (B) Hypoxia delays LEC proliferation. Cell amounts were determine
in medium depleted of VEGF and bFGF by the incorporation of the vital dye neutra
carboxy-DCFDA and exposed to hypoxia at different time points in order to measure
plate reader. (D) LEC experienced major changes in their cytoskeletal architecture upo
24 h in normoxia or hypoxia (1% pO2). All the comparisons between control and hythe extracellular matrix related genes FN1, DDR1, Testican-1,
TGFBI, PLOD2, TNS, and TIMP3 in hypoxia treated LEC
while the differential expression of HALPN1 could not be
confirmed. Lymphotoxin beta (LTB), CXCR4, CXCL5 and
CXCL-12 were chosen for their close relationship with
chemotaxis. All but the first one were upregulated in three
new experiments. Our validation analysis confirmed the
upregulation of 18 out of 22 genes (82%). The low percentage
of false positive proves that it is appropriate to be highly
restrictive when analyzing the primary data set.
Regarding the relative numbers of differentially expressed
genes, we observed that a significant proportion of the regulated
genes were related to basal metabolism (18%) and cell division
(13%). Hence, in agreement with previous published data [10],
gene expression pointed towards a metabolic adaptation
oriented to obtain energy through an increased glucose
metabolism. In fact, genes such as enolase 2 (ENO2) and the
glucose transporters SLC2A1, (8 fold) and SLC2A3, (3.2 fold),
implicated in the glycolytic pathway were induced. We also
observed an increased expression of genes involved in the
reversible production of ATP such as adenylate kinase 1 and 3
(AK1 and AK3).
It seems reasonable to argue that the restriction caused in the
energy supply in LEC due to the lack of oxygen could hold back
their proliferative capabilities. In fact, it has been demonstrated
that hypoxia reduces the proliferation of endothelial cells
through a HIF 1α dependent mechanism [16], In harmony withsed LEC. (A) Differentially expressed genes were grouped according to their
he abundance of transcripts from each category relative to the 469 differentially
d in LEC cultured for 24, 48, 72, 96 and 120 h in normoxia or hypoxia (1% pO2)
l red. (C) Low oxygen levels induced ROS production. Cells were loaded with
ROS production. carboxy-DCFDA oxidation was measured using a fluorescent
n exposure to hypoxia. Phalloidin staining of F-actin filaments in LEC grown for
poxia exposed cells were made using an ANOVA test, ⁎P<0.01, ⁎⁎P<0.005.
Table 2
Differentially regulated genes in LEC under hypoxia associated with cell adhesion, apoptosis, chemotaxis, cytoskeleton and oxidative stress
Chip ID Name Gene symbol Gene ID Mean Probes a
Cell adhesion
217007_s_at a disintegrin and metalloproteinase domain 15 (metargidin) ADAM15 AK000667 −2.0 1.0
226545_at CD109 antigen (Gov platelet alloantigens) CD109 AL110152 2.1 1.0
209543_s_at CD34 antigen CD34 M81104 2.0 1.0
203954_x_at claudin 3 CLDN3 NM_001306 3.4 2.0
52255_s_at collagen, type V, alpha 3 COL5A3 AI984221 −8.6 1.0
202099_s_at DiGeorge syndrome critical region gene 2 DGCR2 H42875 −5.3 1.0
227609_at epithelial stromal interaction 1 (breast) EPSTI1 AA633203 2.3 1.0
1558199_at fibronectin 1 FN1 W73431 6.1 1.0
205523_at hyaluronan and proteoglycan link protein 1/Crtl1 HAPLN1 U43328 39.4 1.0
207165_at hyaluronan-mediated motility receptor (RHAMM) HMMR NM_012485 −2.1 1.0
220249_at hyaluronoglucosaminidase 4 HYAL4 NM_012269 2.8 1.0
207029_at KIT ligand KITLG NM_000899 −2.0 1.0
206677_at keratin, hair, acidic, 1 KRTHA1 NM_002277 −4.6 1.0
205876_at leukemia inhibitory factor receptor LIFR NM_002310 −2.1 1.0
213640_s_at lysyl oxidase LOX BE503425 4.1 3.0
207543_s_at procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase),
alpha polypeptide I
P4HA1 NM_000917 2.8 1.0
228635_at protocadherin 10 PCDH10 AI640307 2.3 1.0
219656_at protocadherin 12 PCDH12 NM_016580 2.5 1.0
205534_at BH-protocadherin (brain-heart) PCDH7 NM_002589 −2.3 1.0
219737_s_at protocadherin 9 PCDH9 AI524125 −2.3 1.0
202619_s_at procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2 PLOD2 AI754404 2.1 1.0
228121_at transforming growth factor, beta 2 TGFB2 AU145950 2.1 1.0
201506_at transforming growth factor, beta-induced, 68 kDa TGFBI NM_000358 3.5 1.0
201148_s_at tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory) TIMP3 AW338933 2.8 4.0
Apoptosis
222343_at BCL2-like 11 (apoptosis facilitator) BCL2L11 AA629050 −2.5 1.0
1555826_at baculoviral IAP repeat-containing 5 (survivin) BIRC5 BQ021146 −2.6 1.0
211214_s_at death-associated protein kinase 1 DAPK1 BC003614 −2.5 1.0
205488_at granzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3) GZMA NM_006144 3.7 1.0
201631_s_at immediate early response 3 IER3 NM_003897 2.1 1.0
213338_at Ras-induced senescence 1 RIS1 BF062629 22.6 1.0
202687_s_at tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 U57059 −2.1 2.0
Chemotaxis and growth factors
202912_at adrenomedullin ADM NM_001124 3.2 1.0
215101_s_at chemokine (C–X–C motif) ligand 5 CXCL5 BG166705 2.6 2.0
217028_at chemokine (C–X–C motif) receptor 4 CXCR4 AJ224869 3.8 3.0
223648_s_at fibroblast growth factor receptor-like 1 FGFRL1 AF279689 −2.1 1.0
217502_at interferon-induced protein with tetratricopeptide repeats 2 IFIT2 BE888744 −2.1 2.0
205227_at interleukin 1 receptor accessory protein IL1RAP NM_002182 5.3 1.0
234066_at interleukin 1 receptor-like 1 IL1RL1 AL117622 −2.4 2.0
203233_at interleukin 4 receptor IL4R NM_000418 2.1 1.0
204864_s_at interleukin 6 signal transducer (gp130) IL6ST NM_002184 −2.3 3.0
201983_s_at epidermal growth factor receptor EGFR AW157070 3.2 1.0
234725_s_at sema domain, (semaphorin) 4B SEMA4B AK026133 2.3 1.0
208124_s_at sema domain, (semaphorin) 4F SEMA4F NM_004263 −3.0 1.0
210512_s_at vascular endothelial growth factor VEGF AF022375 4.0 4.0
209946_at vascular endothelial growth factor C VEGFC U58111 2.8 1.0
Cytoeskeleton
204177_s_at kelch-like ECT2 interacting protein KLEIP NM_014458 2.3 1.0
1552619_a_at anillin, actin binding protein (scraps homolog, Drosophila) ANLN NM_018685 −2.5 2.0
209083_at coronin, actin binding protein, 1A CORO1A U34690 −5.7 1.0
209789_at coronin, actin binding protein, 2B CORO2B BF939649 2.0 1.0
1007_s_at discoidin domain receptor family, member 1 DDR1 U48705 2.0 2.0
220636_at dynein, axonemal, intermediate polypeptide 2 DNAI2 NM_023036 −12.1 1.0
212339_at erythrocyte membrane protein band 4.1 like 1 EPB41L1 AL121895 2.0 1.0
211776_s_at erythrocyte membrane protein band 4.1 like 3 EPB41L3 BC006141 2.3 3.0
223427_s_at erythrocyte membrane protein band 4.1 like 4B EPB41L4B AB032179 5.7 1.0
1566269_at GTPase activating Rap/RanGAP domain-like 1 GARNL1 AF085938 −34.3 1.0
235110_at HRAS-like suppressor 3 HRASLS3 BG539238 2.8 1.0
(continued on next page)
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Table 2 (continued)
Chip ID Name Gene symbol Gene ID Mean Probes a
Cytoeskeleton
206364_at kinesin family member 14 KIF14 NM_014875 −2.0 1.0
218355_at kinesin family member 4A KIF4A NM_012310 −2.5 1.0
238328_at myosin phosphatase-Rho interacting protein M-RIP BF312839 −3.5 1.0
237206_at myocardin MYOCD AI452798 4.9 1.0
224774_s_at neuron navigator 1 NAV1 AK022622 2.2 3.0
202150_s_at neural precursor cell expressed, developmentally down-regulated 9 NEDD9 U64317 2.0 1.0
222680_s_at RA-regulated nuclear matrix-associated protein RAMP AK001261 −2.0 1.0
204543_at Rap guanine nucleotide exchange factor (GEF) 1 RAPGEF1 NM_005312 −2.3 1.0
201747_s_at scaffold attachment factor B SAFB AI769566 −2.0 1.0
202796_at synaptopodin SYNPO NM_007286 2.6 1.0
221747_at tensin TNS AL046979 4.0 2.0
238688_at tropomyosin 1 (alpha) TPM1 AI521618 2.5 1.0
210052_s_at microtubule-associated protein homolog TPX2 AF098158 −2.0 1.0
Oxidative stress
203946_s_at arginase, type II ARG2 U75667 2.3 1.0
223046_at egl nine homolog 1 (C. elegans) EGLN1 AL117352 2.5 3.0
222847_s_at egl nine homolog 3 (C. elegans) EGLN3 AI378406 29.1 2.0
225750_at ERO1-like (S. cerevisiae) ERO1L BE966748 2.5 2.0
204818_at hydroxysteroid (17-beta) dehydrogenase 2 HSD17B2 NM_002153 3.2 1.0
226682_at hypothetical protein LOC283666 LOC283666 AW006185 2.1 1.0
219773_at NADPH oxidase 4 NOX4 NM_016931 2.0 1.0
201468_s_at NAD(P)H dehydrogenase, quinone 1 NQO1 NM_000903 −2.2 2.0
213599_at Opa-interacting protein 5 OIP5 BE045993 −2.5 1.0
213131_at olfactomedin 1 OLFM1 R38389 −2.1 1.0
a Number of differentially expressed probes.
886 M. Irigoyen et al. / Biochimica et Biophysica Acta 1773 (2007) 880–890this, our microarray expression data suggested an overall anti-
proliferative effect of hypoxia on LEC, since proteins involved
in cell cycle progression such as the cyclins A2 (0.46 fold), B1
(0.43 fold) and F (0.46 fold), or the cyclin dependent
components CDC 2 and 6 were repressed. At the same time,
genes involved in the abrogation of cell division such as inhibin
A (INHBA, 2.46 fold), a member of the TGFβ response
proteins [17] or the dual specificity phosphatase 1 (DUSP1/
MKP-1, 2.07 fold) [18], were significantly induced.
These results obtained at the genome level were supported
by experimental evidences obtained in cell proliferation assays.
As expected, cells grown in normoxia kept dividing at their
regular speed while hypoxia exposed LEC showed delayed
proliferation (Fig. 2B). In light of the results obtained, we
postulated that the delay observed in cell division could also
have been a consequence of the onset of an apoptotic response.
Therefore, we checked the viability of the LEC cell population
24 h after chronic hypoxia exposure by means of the annexin-V/
PI flow cytometric assay. We observed that LEC were viable
after being cultured under hypoxia since they were devoid of
both annexin and PI staining (98.23% and 98.6% for normoxic
and hypoxic LEC respectively).
Nevertheless, since cell fate under stress condition is
determined by a delicate balance between factors that induce
or counteract apoptosis, it was not surprising to find a
concurrent regulation in the expression of some anti- and pro-
apoptotic factors (Table 2). For example, IER3/IEX1 (2.1 fold),
which protects the cell from TNF-α induced apoptosis [19], was
upregulated along with genes involved in well known apoptotic
pathways such as granzime A (3.7 fold) [20]. We then turnedour attention to the expression of genes related to oxidative
metabolism since, in situations of low oxygen availability, a
deregulation of the electron transport chain leads to the
production of toxic radicals [21]. Accordingly, mRNA levels
of the enzyme NADPH oxidase 4, the main source of ROS in
endothelium [22] rose (2 fold). Simultaneous measurements of
the production of reactive oxygen species under low oxygen
conditions by LEC were performed showing that ROS
production was an early event (30–60 min) reaching baseline
levels 6 h after hypoxic exposure (Fig. 2C). One explanation of
the restitution of ROS to baseline levels could be the
concomitant rise (1.6 fold) in the expression of superoxide
dismutase 2, one of the components of the antioxidant system
[23].
It has been shown that endothelial cells experience major
changes in their actin scaffold under oxidative stress [24]. In a
hypoxic milieu, LEC responded with a strong upregulation of
several genes involved in actin dynamics such as EPB41L1 and
3 implicated in cortical actin organization as well as CORO2B,
which regulates the formation of nucleation complexes [25]
(Table 2). Phalloidin staining of F-actin filaments confirmed the
changes observed in the cellular scaffold after hypoxia exposure
by gene expression analysis (Fig. 2D).
The changes in the reorganization of the cytoskeleton are
usually accompanied by variations in their ECM binding
capabilities. In fact, it has been demonstrated that in challenging
environments such as hypoxia, blood endothelial cells respond
with increased adhesion to cell substrate [26] through the
synthesis of extracellular matrix proteins such as collagen [12].
Giving the importance of endothelial cell migration and
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the changes in their adhesive features induced by hypoxia
deserved more attention. In fact, more than 10% of LEC
differentially regulated genes corresponded to molecules
involved in cell adhesion and chemotaxis. We therefore
hypothesized that under hypoxia, LEC could also suffer
variations in their attachment to the extracellular matrix.
To study this matter, we performed adhesion experiments to
several extracellular matrix components using hypoxia and
normoxia exposed LEC. As expected, hypoxia increased the
adhesion of LEC to ECM proteins, which was stronger in the
cases of collagens I, IVand fibronectin (Fig. 3A). This increased
cell binding was dependent on the presence of a hypoxic milieu
since the reoxygenation of LEC restored their adhesion to
baseline levels. The transcriptional upregulation of genes
corresponding to several cell matrix binding proteins such asFig. 3. LEC changed their adhesive properties in response to hypoxia. (A)
Endothelial cells were loaded with calcein and allowed to adhere to different
extracellular matrix proteins, after being grown in normoxia (white columns) or
hypoxia (black columns, 1% pO2) for 24 h or cultured for 24 h under hypoxia
and further reoxygenated for 6 h (lined columns). BSA was used as negative
control. (B and C) H1299, H-157 and A549 NSCLC cells were cultured for 24 h
under normoxia, hypoxia (1% pO2) and hypoxia or exposed to hypoxia plus a
subsequent reoxygenation for 6 h. NSCLC were calcein labeled and allowed to
adhere for 2 h on a LECmonolayer that had been grown for 24 h under normoxia
(B) or hypoxia (1% pO2) (C). NSCLC were treated with IL-1β 10 ng/ml for 24 h
as positive adhesion control. Comparisons between control and hypoxia
exposed cells were made using an ANOVA test, ∗P<0.01, ∗∗P<0.005.the collagen binding protein discoidin domain receptor 1
(DDR1) [27] and tensin, a focal adhesion protein related with
increased adhesion to fibronectin [28], gave us a relationship
between functional and transcriptional data (Table 2). More-
over, we found that LEC grown under hypoxic conditions
underwent major increases in the mRNA expression levels of
extracellular proteins such as fibronectin (6 fold), and TGFBI
(TGF beta induced I, 3.5 fold) which mediates cell adhesion to
the ECM [29]. At the same time, matrix degradation seemed to
be inhibited, since there was a diminished expression of the
matrix metalloproteinase ADAM15 and a rise in the mRNA
levels of the tissue inhibitor of metalloproteinase TIMP3 (Table
2). It has been recently described how ECM molecules and
matrix metalloproteinases play a key role in regulating LEC
growth, migration, and survival [30]. It was noteworthy that in
spite of the increased adhesion to extracellular matrix proteins,
the expression of key molecules involved in cell adhesion such
as the integrins was not altered. A possible explanation for these
results could be that the augmented cell adhesion is being
mediated by integrin adaptor proteins such as the aforemen-
tioned TGFBI. This protein has been described as mediating cell
adhesion and migration of synovial fibroblasts [31]. Further
work is needed to clarify this point.
Numerous observations performed on clinical samples
suggest that the lymphatic vessels are the initial means of
tumor dissemination [32]. As a matter of fact, the peritumoral
areas of a great variety of solid carcinomas show higher
lymphatic vessel density as they become more malignant [33].
Compelling experimental evidence demonstrates that cancer
cells use similar mechanisms to metastasize to those which
regulate the trafficking of normal cells throughout the
endothelium. In all these processes, chemokine–chemokine
receptor interactions are of critical importance [34]. Of all the
chemokines involved, stromal-derived factor-1 (SDF-1/
CXCL12), and its receptor CXCR4, play a significant role in
the regulation of cell trafficking [35]. In fact, CXCR4 is
expressed in numerous tumor cells, allowing them to acquire the
ability to metastasize to those organs that secrete CXCL12 [36].
Taking this into account, we find it appealing to ascertain the
functional implication of the increased expression observed in
the expression of CXCL12 (1.8 fold) and of its receptor CXCR4
in LEC exposed to hypoxia.
We consequently moved on to elucidate, on the one hand,
whether hypoxia could be promoting tumor cell adhesion to
the endothelium, and on the other hand, whether the increased
expression observed in CXCR4 could be mediating this effect.
To ascertain this, we performed in the first place tumor-LEC
adhesion experiments under normoxic and hypoxic conditions
using the NSCLC cell lines A549, H157 and H1299. We
observed that tumor cells experienced increased adhesion to
LEC when they had been cultured for 24 h under low oxygen
conditions (Fig. 3B) but surprisingly, the exposure of LEC to
hypoxia did not augment NSCLC adhesion further (Fig. 3C).
Secondly, we determined by flow cytometry whether hypoxia
led to increased expression of CXCR4 molecules in the LEC
and NSCLC cell surface. A discrepancy between CXCR4
mRNA and protein expression has been found in some types
Table 3
Real time RT-PCR quantitation of transcripts differentially expressed
Gene Fold induction (±SD)
INHBA 2.1 (0.2)
ARG2 3.0 (0.1)
SOD2 2.7 (0.1)
NOX4 2.0 (0.4)
PCDH10 2.2 (0.2)
PCDH12 2.4 (0.3)
CD109 1.5 (0.05)
CD34 2.3 (0.34)
CLDN3 1.12 (0.12)
EPSLT1 1.03 (0.08)
FN1 2.7 (0.3)
LOX 2.6 (0.7)
DDR1 1.8 (0.2)
TESTICAN 1.8 (0.1)
TGFBI 2.3 (0.5)
LOX 2.64 (0.69)
TNS 4.5 (0.4)
TIMP3 2.5 (0.4)
HALPN1 1.21 (0.14)
LTB 1.02 (0.12)
CXCR4 2.8 (0.4)
CXCL5 3.4 (0.1)
CXCL12 1.7 (0.2)
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increased mRNA measures are not good indicators of higher
receptor availability [37]. In line with this, we were able to
determine that while CXCR4 mRNA levels doubled afterFig. 4. Involvement of the CXCL12–CXCR4 axis in LEC response to hypoxia. (A) L
and NSCLC cell lines A-549, H-157 and H1299 as measured by flow cytometric ana
line: reoxygenated LEC. Control IgG is shown for each cell line. (B) CXCL12 cyto
ELISA assay (1% pO2).being cultured under hypoxia (Tables 2 and 3), CXCR4
surface expression increased only around 15% in hypoxia
exposed LEC (Fig. 4A). We also measured CXCR4 cell
surface expression in hypoxia exposed NSCLC cells, obtaining
the same results (Fig. 4C). It therefore seemed reasonable to
conjecture that it is not only the increases observed in the
presence of CXCR4 molecules in the LEC and/or tumor
surface which are responsible for the enhanced adhesion, but
perhaps also the augmented secretion of its ligand CXCL12/
SDF-1 by LEC, as suggested by the results of the array. To
further demonstrate this, we determined by ELISA the amount
of CXCL-12 secreted by LECs cultured under hypoxia
verifying that this cytokine is accumulated in the extracellular
media throughout low oxygen exposure (Fig. 4B), which
points toward its possible implication in the attraction of
NSCLC towards the endothelial cells.
Lastly, to further demonstrate the implication of CXCR4 in
NSCLC migration through this endothelium, we tested whether
tumor cell adhesion to the lymphatic endothelium could be
blocked by the use of an anti-CXCR4 antibody. As can be
inferred from Fig. 5A, tumor cell adhesion to LEC is impaired
by an anti-CXCR4 blocking antibody, while it was not reduced
when tumor cells were pre-incubated with a non-specific IgG.
There is growing evidence that CXCL12 and CXCR4 regulate
the migration and metastasis of lung cancer cells [38]. Given the
implication of this molecule in tumor cell adhesion to LEC, we
examined whether the use of CXCR4 blocking antibodies could
also impair NSCLC migration through this endothelium.ow oxygen levels increased the expression of CXCR4 on the cell surface of LEC
lysis. Continuous line: normoxia, shadowed line: hypoxia exposed LEC, dotted
kine accumulated in the supernatant of LECs exposed to hypoxia measured by
Fig. 5. CXCR4 mediated NSCLC binding and migration through LEC. (A) NSCLC adhesion to LEC is CXCR4 mediated. A549, H-157 and H-1299 NSCLC cells
were grown for 24 h in normoxia (NOR), hypoxia (HYP) or hypoxia and further reoxygenated for 6 h. NSCLC were also treated with 10 ng/ml IL-1β for 24 h as a
positive adhesion control. Adhesion assays were performed on LEC monolayers as described in Materials and methods. The addition of an anti-CXCR4 blocking
antibody (5 ng/ml, α-CXCR4), significantly reduced the adhesion of all the NSCLC cell lines tested while a non-specific IgG rendered basal adhesion levels. (B)
A549, H-157 and H1299 NSCLC cell migration through LEC endothelial layers was measured in Boyden chambers. Tumor cells were grown under normoxia (NOR)
or hypoxia (HYP) for 24 h. The increase observed in cell migration after hypoxia exposure was blocked by the addition of an anti-CXCR4 antibody (5 ng/ml,
α-CXCR4). Comparisons in cell adhesion and migration were made using an ANOVA test, ∗P<0.01; ∗∗P<0.005.
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NSCLC migrate to a greater extent when cultured under
hypoxia. Interestingly, CXCR4 seemed an important mediator
for the adherence and migration of tumor cells to LECs, since
the use of a CXCR4 blocking antibody prevented tumor cell
transmigration (Fig. 5B). CXCR4 inhibition is being used to
target metastasis of cancer cells in clinical trials [39]. For this
reason, the fact that the same system was found operating in
lymphatic endothelium provides a rationale for the use of
these inhibitors to impede metastatic spread through the
lymphovascular system.
In summary, the use of microarray technology has provided
us with a powerful tool to portray a complex process such as the
regulation of gene expression during LEC response to hypoxia.
Transcriptional analysis and in vitro functional assays revealed
that hypoxia delayed cell proliferation, whereas it induced ROS
production, the reorganization of the actin scaffold and
increased cell adhesion to the extracellular matrix. The differen-
tial expression of genes such as TGFBI or TIMP3, whoseregulation under low oxygen exposure had not been previously
described, along with others already reported to be hypoxia
responsive such as adrenomedullin, could be mediating these
effects. Moreover, we have demonstrated for the first time the
induction of the CXCL12/CXCR4 axis under hypoxia in this
endothelium and its involvement in tumor cell adhesion to
LEC, constituting a potential target for clinical endeavors.
Therefore, we expect that the data offered above could prove
useful to elucidate the mechanisms involved in lymphatic cell
physiology and present new ways to modulate its adhesive
capabilities.
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